PCOS hair loss treatment is a priority concern for many of the estimated 1 in 10 UK women living with polycystic ovary syndrome. Androgen-driven hair thinning — known as female pattern hair loss or androgenetic alopecia — can significantly affect confidence and quality of life. Fortunately, a range of evidence-based options exist, from licensed medicines such as topical minoxidil and co-cyprindiol to lifestyle changes that address the underlying hormonal imbalance. This guide explains why PCOS causes hair loss, how it is diagnosed in the UK, which treatments are available, and when to seek further support from your GP or a specialist.
Summary: PCOS hair loss treatment involves addressing androgen excess through medicines such as topical minoxidil, co-cyprindiol, or spironolactone, alongside lifestyle changes that improve insulin sensitivity and reduce hormonal drivers of hair thinning.
- PCOS-related hair loss is driven by excess androgens — particularly DHT — which miniaturise scalp hair follicles, causing female pattern hair loss with central parting widening.
- Topical minoxidil (Regaine® for Women) is available over the counter in the UK and is a first-line option; results take 3–6 months and treatment must be continued to maintain benefit.
- Co-cyprindiol and spironolactone are anti-androgen medicines used off-label for PCOS hair loss; both require contraception due to teratogenic risk, and co-cyprindiol carries an increased VTE risk.
- Blood tests including testosterone, SHBG, thyroid function, ferritin, and HbA1c are recommended to identify hormonal and nutritional contributors before starting treatment.
- Lifestyle changes — particularly modest weight loss and a low-GI diet — can lower androgen levels and improve insulin sensitivity, supporting hair loss management in PCOS.
- Signs of virilisation (voice deepening, clitoral enlargement) or markedly elevated testosterone require urgent specialist referral to exclude a rare androgen-secreting tumour.
Table of Contents
Am I eligible for weight loss injections?
Find out whether you might be eligible!
Answer a few quick questions to see whether you may be suitable for prescription weight loss injections (like Wegovy® or Mounjaro®).
- No commitment — just a quick suitability check
- Takes about 1 minute to complete
Why PCOS Causes Hair Loss and Thinning
PCOS causes hair loss through androgen excess — particularly DHT — which miniaturises scalp follicles and shortens the hair growth phase, producing progressive thinning typically along the central parting.
Not sure if this is normal? Chat with one of our pharmacists →
Polycystic ovary syndrome (PCOS) is one of the most common hormonal conditions affecting women of reproductive age in the UK, estimated to affect around 1 in 10 women. One of its more distressing features is hair loss or thinning, a condition clinically referred to as androgenetic alopecia or female pattern hair loss. Understanding why this happens is central to choosing the right PCOS hair loss treatment.
The primary driver is an excess of androgens — male-type hormones such as testosterone and its more potent derivative, dihydrotestosterone (DHT). In women with PCOS, androgen excess is primarily of ovarian origin, although the adrenal glands contribute in a subset of women. DHT binds to receptors in hair follicles on the scalp, causing them to miniaturise over time. This shortens the active growth phase (anagen) of the hair cycle, resulting in progressively finer, shorter hairs and, eventually, visible thinning — typically presenting as widening of the central parting, with the frontal hairline often preserved.
It is important to note that normal serum androgen levels do not exclude female pattern hair loss — genetic sensitivity of hair follicles to androgens plays a significant role, which is why some women with elevated androgen levels notice marked thinning whilst others do not, and why some women with normal androgen levels are also affected. Additionally, insulin resistance, which is common in PCOS, can further stimulate androgen production, compounding the problem. Conditions such as thyroid dysfunction or iron deficiency anaemia can also contribute to hair thinning and should be excluded as part of a thorough assessment.
Further information: NICE Clinical Knowledge Summary: Polycystic ovary syndrome; NHS: Polycystic ovary syndrome overview; British Association of Dermatologists patient information: Female pattern hair loss.
| Treatment | Type | Mechanism | Typical Dose | Key Side Effects | Important Warnings | UK Licensing Status |
|---|---|---|---|---|---|---|
| Co-cyprindiol (Dianette®) | Combined oral contraceptive / anti-androgen | Blocks androgen receptors; suppresses ovarian androgen production | One tablet daily per cycle | Nausea, breast tenderness, mood changes | Increased VTE risk vs standard COC (MHRA); avoid in cardiovascular or liver disease | Licensed for severe acne/hirsutism; off-label for PCOS hair loss |
| Spironolactone | Anti-androgen (oral) | Competitively inhibits DHT at hair follicle receptors | 50–200 mg daily, titrated to response | Menstrual irregularity, breast tenderness, dizziness, increased urination | Teratogenic; reliable contraception essential; monitor potassium and blood pressure | Off-label for hair loss and PCOS in UK |
| Minoxidil (Regaine® for Women) | Topical hair growth treatment | Prolongs anagen phase; improves follicular blood supply | 2% solution twice daily or 5% foam once daily | Initial shedding, scalp irritation, facial hypertrichosis | Not recommended in pregnancy or breastfeeding; must continue to maintain benefit | Licensed OTC for female pattern hair loss |
| Metformin | Biguanide / insulin sensitiser (oral) | Reduces insulin resistance, indirectly lowering androgen levels | Consult SmPC | Nausea, diarrhoea, gastrointestinal upset | Limited evidence for direct benefit on alopecia; best used for metabolic management | Off-label for PCOS hair loss; licensed for type 2 diabetes |
| Finasteride / Dutasteride | 5-alpha reductase inhibitors (oral) | Reduce conversion of testosterone to DHT | Specialist-initiated; consult SmPC | Teratogenic risk, menstrual changes | Highly effective contraception required during and after treatment; specialist only | Not routinely available via NHS for this indication; specialist off-label use |
| Weight management (lifestyle) | Lifestyle intervention | 5–10% weight loss lowers androgens and improves insulin sensitivity | Low-GI diet, regular exercise | None | NICE CKS recommends as first-line approach in PCOS management | N/A — non-prescription |
| Nutritional supplementation (iron, zinc, vitamin D) | Dietary supplement | Corrects deficiencies associated with hair thinning | As directed; supplement only if deficiency confirmed | High-dose biotin can interfere with TFTs and troponin assays | Inform GP if taking biotin before blood tests; do not supplement without confirmed deficiency | N/A — non-prescription |
How PCOS-Related Hair Loss Is Diagnosed in the UK
Diagnosis begins with GP assessment using the Rotterdam criteria, supported by blood tests including testosterone, SHBG, thyroid function, ferritin, and HbA1c to identify hormonal and nutritional contributors.
Diagnosis of PCOS-related hair loss in the UK typically begins with a consultation with your GP, who will take a detailed medical and menstrual history alongside a physical examination. PCOS itself is diagnosed using the Rotterdam criteria, which requires at least two of the following three features: irregular or absent periods, clinical or biochemical signs of excess androgens, and polycystic ovaries on ultrasound.
For hair loss specifically, your GP is likely to request a panel of blood tests to identify hormonal and nutritional contributors. These commonly include:
-
Total and free testosterone — to assess androgen excess
-
Sex hormone-binding globulin (SHBG) — low levels increase free androgen availability
-
DHEA-S (dehydroepiandrosterone sulphate) — considered where an adrenal source of androgen excess is suspected
-
LH and FSH — not required to diagnose PCOS, but may be measured to help exclude other conditions such as premature ovarian insufficiency
-
Thyroid function tests (TFTs) — to rule out hypothyroidism
-
Full blood count and ferritin — to exclude iron deficiency anaemia
-
HbA1c — to screen for impaired glucose regulation or type 2 diabetes; an oral glucose tolerance test (OGTT) may be considered in higher-risk women (e.g., BMI ≥30, family history of type 2 diabetes, or previous gestational diabetes), in line with NICE CKS recommendations. Fasting insulin is not routinely recommended in UK primary care for PCOS assessment
-
Lipid profile and blood pressure — cardiometabolic risk assessment is an important part of PCOS care
-
Pregnancy test — should be considered in women presenting with amenorrhoea
If virilisation is present (see below) or testosterone is markedly elevated, urgent specialist referral is warranted to exclude a rare androgen-secreting tumour.
A pelvic ultrasound may be arranged to visualise the ovaries, though this is not always necessary if other diagnostic criteria are already met. In some cases, a GP may refer to a dermatologist for a more detailed scalp assessment, which can include dermoscopy — a non-invasive technique that examines hair follicle density and miniaturisation patterns. Referral to an endocrinologist or gynaecologist may follow if the hormonal picture is complex or if initial treatments are ineffective.
Further information: NICE Clinical Knowledge Summary: Polycystic ovary syndrome; NICE Clinical Knowledge Summary: Hirsutism; NHS: Polycystic ovary syndrome overview.
Medicines Used to Treat Hair Loss in PCOS
Key medicines include topical minoxidil (over the counter), co-cyprindiol, and off-label spironolactone; all require ongoing use and carry specific safety considerations including teratogenicity and, for co-cyprindiol, increased VTE risk.
Several medicines are used in the UK to address PCOS-related hair loss, targeting either the underlying hormonal imbalance or the hair follicle directly. It is important to have realistic expectations — most treatments slow further loss and promote partial regrowth rather than fully restoring previous hair density. Always discuss the suitability of any medicine with your prescriber, taking into account your individual medical history.
Co-cyprindiol (e.g., Dianette®) is a combined oral contraceptive containing cyproterone acetate (an anti-androgen) and ethinylestradiol. It is licensed in the UK as a second-line treatment for severe acne and moderately severe hirsutism in women, and is used off-label to help with androgen-related hair thinning in PCOS. It works by blocking androgen receptors and suppressing ovarian androgen production. The MHRA advises that co-cyprindiol carries a small but increased risk of venous thromboembolism (VTE) compared with standard combined oral contraceptives, and it should not be used solely as a contraceptive. It should be discontinued three to four cycles after the condition has resolved. Women with risk factors for VTE, cardiovascular disease, or liver disease should discuss these with their prescriber before use.
Spironolactone, though not licensed in the UK specifically for hair loss or PCOS, is widely used off-label as an anti-androgen. It competitively inhibits DHT at the hair follicle receptor level. Typical doses used in clinical practice range from 50 to 200 mg daily, titrated according to response and tolerability. Common adverse effects include menstrual irregularity, breast tenderness, dizziness, and increased urinary frequency. Baseline and periodic monitoring of potassium levels (U&Es) and blood pressure is required. Spironolactone is teratogenic and must not be used during pregnancy; women of childbearing potential must use reliable contraception throughout treatment.
Experiencing these side effects? Our pharmacists can help you navigate them →
Minoxidil (available as Regaine® for Women in the UK) is a topical treatment applied directly to the scalp. It is available over the counter in 2% solution (applied twice daily) and 5% foam (applied once daily) formulations for women. Its exact mechanism in hair growth is not fully understood, but it is thought to prolong the anagen phase and improve follicular blood supply. An initial increase in hair shedding during the first few weeks of use is common and does not indicate treatment failure. Other possible side effects include scalp irritation and, occasionally, unwanted facial hair (hypertrichosis). Results typically take three to six months to become apparent, and treatment must be continued to maintain benefit. Minoxidil is not recommended during pregnancy or breastfeeding; seek medical advice before use if you are pregnant, planning a pregnancy, or breastfeeding.
Metformin is used primarily to address insulin resistance in PCOS and may indirectly reduce androgen levels. It is not licensed for the treatment of hair loss, and evidence for meaningful benefit on alopecia specifically remains limited. Its role is best understood as part of broader metabolic management of PCOS rather than as a direct hair loss treatment.
Other anti-androgens such as finasteride or dutasteride are occasionally used by specialists for female pattern hair loss, but these are initiated by specialists only, carry a significant teratogenic risk, and require highly effective contraception throughout treatment and for a period after stopping. They are not routinely available through NHS pathways for this indication.
Reporting side effects: If you experience a suspected side effect from any medicine, you can report it directly to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.
Further information: MHRA/EMC SmPC: Co-cyprindiol (Dianette/co-cyprindiol); MHRA Drug Safety Update: Cyproterone acetate/ethinylestradiol — VTE risk; MHRA/EMC SmPC: Topical minoxidil (Regaine for Women); BNF monographs: co-cyprindiol, spironolactone, minoxidil, metformin.
Lifestyle and Non-Prescription Approaches That May Help
A 5–10% reduction in body weight and a low-GI diet can lower androgen levels and improve insulin sensitivity, making lifestyle change a NICE-recommended first-line component of PCOS hair loss management.
Alongside medical treatments, a number of lifestyle modifications and non-prescription strategies can support PCOS hair loss management. These approaches work best as part of a holistic plan rather than as standalone solutions.
Weight management is one of the most evidence-supported interventions in PCOS. Even a modest reduction in body weight of 5–10% in women who are overweight has been shown to lower androgen levels, improve insulin sensitivity, and reduce the hormonal drivers of hair loss. A balanced, low-glycaemic index (low-GI) diet — rich in vegetables, wholegrains, lean protein, and healthy fats — can help stabilise blood glucose and insulin levels, which in turn may reduce androgen production. NICE CKS recommends lifestyle intervention as a first-line approach in PCOS management.
Nutritional support is also worth considering. Deficiencies in iron, zinc, and vitamin D have been associated with hair thinning, and correcting these through diet or supplementation where deficiency is confirmed may support hair health. Biotin is often marketed for hair health; however, evidence for its benefit in the absence of confirmed deficiency is limited. Importantly, high-dose biotin supplements can interfere with certain laboratory blood tests (including thyroid function tests and cardiac troponin assays), potentially producing misleading results. If you are taking biotin supplements, inform your GP and consider pausing them before any blood tests, in line with local laboratory advice. Supplementing with any nutrient without a confirmed deficiency is generally not recommended and should be discussed with a healthcare professional.
From a hair care perspective, gentle practices can help minimise further breakage and loss:
-
Avoid tight hairstyles such as high ponytails or braids that place tension on the scalp
-
Use mild, sulphate-free shampoos and avoid excessive heat styling
-
Allow hair to air-dry where possible
Stress management is another important consideration, as chronic psychological stress can exacerbate hair shedding through a mechanism known as telogen effluvium. Techniques such as mindfulness, regular physical activity, and adequate sleep may all contribute positively. Some women also find benefit from speaking with a counsellor or psychologist, particularly given the emotional impact that visible hair loss can have on self-esteem and quality of life.
Further information: NICE Clinical Knowledge Summary: Polycystic ovary syndrome (lifestyle and metabolic risk); NHS: Polycystic ovary syndrome — management; British Association of Dermatologists patient information: Female pattern hair loss.
When to Seek Further Support from Your GP or Specialist
Seek prompt GP review for sudden or patchy hair loss, signs of virilisation, or no improvement after six months of treatment; virilisation or markedly elevated testosterone warrants urgent specialist referral.
Knowing when to escalate your concerns is an important part of managing PCOS-related hair loss safely and effectively. Whilst some degree of hair shedding is a normal part of the hair cycle, certain signs warrant prompt medical attention.
Contact your GP if you notice:
-
Sudden or rapidly progressive hair loss over a short period
-
Patchy hair loss, which may suggest alopecia areata — an autoimmune condition unrelated to PCOS
-
Hair loss accompanied by other new symptoms such as significant weight gain, fatigue, cold intolerance, or changes in skin texture (which may indicate thyroid dysfunction)
-
Signs of significant androgen excess, including deepening of the voice, clitoral enlargement, or rapidly worsening hirsutism — these features of virilisation, or a markedly elevated testosterone level, should prompt urgent referral to endocrinology or gynaecology to exclude a rare androgen-secreting tumour
-
No improvement after six months of consistent treatment with minoxidil or other prescribed therapies
-
Recent significant illness, major surgery, rapid weight loss, or new medicines, as these can trigger a temporary increase in hair shedding (telogen effluvium); a review of your current medicines with your GP may be helpful
If your GP feels that your hair loss is not adequately controlled in primary care, referral to a consultant dermatologist or endocrinologist is appropriate. In some NHS trusts, specialist PCOS clinics exist that offer multidisciplinary input from gynaecology, endocrinology, and dietetics. Private dermatology services offering platelet-rich plasma (PRP) therapy or low-level laser therapy (LLLT) are also available, though evidence for these in PCOS-specific hair loss remains emerging and they are not currently recommended within NHS pathways.
Finally, the psychological burden of hair loss should never be underestimated. If hair thinning is significantly affecting your mental health or daily functioning, do not hesitate to raise this with your GP, who can refer you to appropriate psychological support services.
Further information: NICE Clinical Knowledge Summary: Hirsutism (urgent referral indicators); NHS: Hair loss — when to see a GP.
Frequently Asked Questions
How long does PCOS hair loss treatment take to work?
Most PCOS hair loss treatments, including topical minoxidil, take three to six months before visible improvement is noticeable. Anti-androgen medicines such as spironolactone or co-cyprindiol may also take several months to show meaningful benefit, and treatment must be continued to maintain results.
Can PCOS hair loss grow back, or is it permanent?
Partial regrowth is possible with appropriate PCOS hair loss treatment, particularly if started before significant follicle miniaturisation has occurred. Most treatments slow further loss and encourage some regrowth rather than fully restoring previous hair density, so early intervention gives the best outcome.
Is minoxidil safe to use if I have PCOS?
Topical minoxidil is generally considered safe for women with PCOS and is available over the counter in the UK as Regaine® for Women. It should not be used during pregnancy or breastfeeding, and you should seek medical advice before starting if you are planning a pregnancy or have any underlying health conditions.
What is the difference between spironolactone and co-cyprindiol for PCOS hair loss?
Both are anti-androgen treatments used off-label for PCOS-related hair loss, but they work differently: co-cyprindiol is a combined oral contraceptive that also blocks androgen receptors, while spironolactone is a standalone anti-androgen tablet that directly inhibits DHT at the hair follicle. Co-cyprindiol carries an increased VTE risk compared with standard contraceptive pills, whereas spironolactone requires monitoring of potassium levels and blood pressure.
Can I get PCOS hair loss treatment on the NHS?
Yes, several treatments are available through the NHS — your GP can prescribe co-cyprindiol or spironolactone where clinically appropriate, and topical minoxidil is available over the counter without a prescription. If primary care treatments are insufficient, your GP can refer you to a dermatologist or endocrinologist for specialist assessment.
Could something other than PCOS be causing my hair loss?
Yes — thyroid dysfunction, iron deficiency anaemia, and alopecia areata can all cause hair thinning and should be excluded through blood tests before attributing hair loss solely to PCOS. Your GP will typically check thyroid function, ferritin, and a full blood count as part of the initial assessment.
The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.
The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.
Any third-party brands or services referenced on this site are included for informational purposes only; we are entirely independent and have no affiliation, partnership, or collaboration with any companies mentioned.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Heading 6
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
- Item 1
- Item 2
- Item 3
Unordered list
- Item A
- Item B
- Item C
Bold text
Emphasis
Superscript
Subscript
